ProCE Banner Activity

Phase II PALMIRA: Second-line ET ± Palbociclib Maintenance in Patients With HR+/HER2- Advanced Breast Cancer After Clinical Benefit on First-line Palbociclib + ET

Conference Coverage
Slideset

No PFS improvement was associated with second-line palbociclib maintenance plus an alternative ET following progression after clinical benefit on first-line palbociclib-based therapy in patients with HR+/HER2- advanced breast cancer.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.